{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:26:58Z","timestamp":1762928818002,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-UK-380-5352"],"award-info":[{"award-number":["IN-UK-380-5352"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and polypharmacy, are common in ageing people with HIV, there is a need for alternative efficacious regimens. bPI-based regimens are often the treatment of choice for individuals with pre-treatment or treatment-acquired resistance but it is plausible that carefully selected HIV-positive individuals with drug resistance, who are virologically suppressed on their current bPI regimen, could maintain virological efficacy when switched to bictegravir, emtricitabine and tenofovir alafenamide (B\/F\/TAF) fixed dose combination (FDC).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods\/design<\/jats:title>\n<jats:p>A phase IV, investigator-initiated, multicentre, open label pilot, randomised two-arm study to assess the safety and efficacy of switching from bPI regimen to B\/F\/TAF single tablet regimen in integrase inhibitor-na\u00efve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations. Eligible individuals will either continue on their bPI regimen or switch to B\/F\/TAF FDC. After 24\u2009weeks, all participants in the bPI arm will be switched to B\/F\/TAF and followed for a further 24\u2009weeks and all participants will be followed for 48\u2009weeks. The primary efficacy endpoint is the proportion of participants with HIV-1 RNA &lt;\u200950 copies\/mL at week 24 using pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA &lt;\u200950 copies\/mL at Week 48. Other secondary outcome measures include between arm comparisons of drug resistance at virological failure, safety and tolerability and patient-reported outcome measures.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>We aim to provide preliminary evidence of the efficacy of switching to B\/F\/TAF in patients with virological suppression on a bPI-based regimen who harbour select drug resistance mutations.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/search?q=44453201\">ISRCTN 44453201<\/jats:ext-link>, registered 19 June 2019 and EudraCT 2018\u2013004732-30.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12879-020-05240-y","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T11:03:32Z","timestamp":1595243012000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na\u00efve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-1717","authenticated-orcid":false,"given":"Collins C.","family":"Iwuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Bremner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicky","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Geretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"issue":"6","key":"5240_CR1","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","volume":"5","author":"L Ryom","year":"2018","unstructured":"Ryom L, Lundgren JD, El-Sadr W, Reiss P, Kirk O, Law M, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:a:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291\u2013300.","journal-title":"Lancet HIV"},{"issue":"10","key":"5240_CR2","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/aid.2011.0327","volume":"28","author":"JA Aberg","year":"2012","unstructured":"Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, et al. Metabolic effects of darunavir\/ritonavir versus atazanavir\/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retrovir. 2012;28(10):1184\u201395.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"3","key":"5240_CR3","doi-asserted-by":"publisher","first-page":"e1001809","DOI":"10.1371\/journal.pmed.1001809","volume":"12","author":"A Mocroft","year":"2015","unstructured":"Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, et al. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:a:D study. PLoS Med. 2015;12(3):e1001809.","journal-title":"PLoS Med"},{"issue":"7","key":"5240_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M14-1084","volume":"161","author":"JL Lennox","year":"2014","unstructured":"Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161(7):461\u201371.","journal-title":"Ann Intern Med"},{"issue":"21","key":"5240_CR5","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"N Friis-Moller","year":"2003","unstructured":"Friis-Moller N, Sabin CA, Weber R, d\u2019Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993\u20132003.","journal-title":"N Engl J Med"},{"issue":"1","key":"5240_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/QCO.0000000000000425","volume":"31","author":"J Lundgren","year":"2018","unstructured":"Lundgren J, Mocroft A, Ryom L. Contemporary protease inhibitors and cardiovascular risk. Curr Opin Infect Dis. 2018;31(1):8\u201313.","journal-title":"Curr Opin Infect Dis"},{"issue":"7","key":"5240_CR7","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347\u2013e56.","journal-title":"Lancet HIV"},{"issue":"18","key":"5240_CR8","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","volume":"31","author":"JM Gatell","year":"2017","unstructured":"Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31(18):2503\u201314.","journal-title":"AIDS"},{"issue":"11","key":"5240_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/infdis\/jis261","volume":"205","author":"KC Sigaloff","year":"2012","unstructured":"Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis. 2012;205(11):1739\u201344.","journal-title":"J Infect Dis"},{"issue":"12","key":"5240_CR10","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/cid\/cix1108","volume":"66","author":"AJ Stockdale","year":"2018","unstructured":"Stockdale AJ, Saunders MJ, Boyd MA, Bonnett LJ, Johnston V, Wandeler G, et al. Effectiveness of protease inhibitor\/Nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(12):1846\u201357.","journal-title":"Clin Infect Dis"},{"issue":"9712","key":"5240_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","volume":"375","author":"JJ Eron","year":"2010","unstructured":"Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396\u2013407.","journal-title":"Lancet"},{"key":"5240_CR12","volume-title":"Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir\/Ritonavir (LPV\/r) Plus 2 NRTIs in Second-line Treatment: 48-Week Data From the DAWNING Study","author":"M Aboud","year":"2018","unstructured":"Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo J, Mamedova E, et al. Superior Efficacy of Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir\/Ritonavir (LPV\/r) Plus 2 NRTIs in Second-line Treatment: 48-Week Data From the DAWNING Study. Amsterdam: 22nd International AIDS Conference; 2018."},{"key":"5240_CR13","unstructured":"Perez-Valero I, Llibre J, Lazzarin A, di Perri G, Pulido F, Molina J, et al. A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide (E\/C\/F\/TAF) Single-Tablet Regimen in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and\/or M184I (GS-US-292-1824): Week 24 Results. Amsterdam: 22nd International AIDS Conference; 2018."},{"key":"5240_CR14","volume-title":"Resistance analyses of bictegravir\/emtricitabine\/tenofovir alafenamide switch studies","author":"K Andreatta","year":"2018","unstructured":"Andreatta K, Willkom M, Martin R, Chang C, Martin H, Graham H, et al. Resistance analyses of bictegravir\/emtricitabine\/tenofovir alafenamide switch studies. Seattle: CROI; 2018."},{"issue":"9","key":"5240_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.4156","volume":"22","author":"KM Bruner","year":"2016","unstructured":"Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med. 2016;22(9):1043\u20139.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"5240_CR16","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S0895-4356(01)00449-8","volume":"54","author":"AC Justice","year":"2001","unstructured":"Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77\u201390.","journal-title":"J Clin Epidemiol"},{"key":"5240_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1477-7525-11-164","volume":"11","author":"KN Simpson","year":"2013","unstructured":"Simpson KN, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, et al. Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health Qual Life Outcomes. 2013;11:164.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"5240_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"issue":"5","key":"5240_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"D Wohl","year":"2018","unstructured":"Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus co-formulated Abacavir, Dolutegravir, and lamivudine. Patient. 2018;11(5):561\u201373.","journal-title":"Patient"},{"issue":"6","key":"5240_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/apc.2012.0044","volume":"26","author":"EJ Edelman","year":"2012","unstructured":"Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC, Vacs Project T. Patient-reported symptoms on the antiretroviral regimen efavirenz\/emtricitabine\/tenofovir. AIDS Patient Care STDs. 2012;26(6):312\u20139.","journal-title":"AIDS Patient Care STDs"},{"key":"5240_CR21","doi-asserted-by":"publisher","first-page":"i5239","DOI":"10.1136\/bmj.i5239","volume":"355","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.","journal-title":"BMJ"},{"key":"5240_CR22","volume-title":"Guide to the General Data Protection Regulation (GDPR)","author":"ICO","year":"2019","unstructured":"ICO. Guide to the General Data Protection Regulation (GDPR) 2019 [updated May 2019; cited 30 Dec 2019. Available from: https:\/\/ico.org.uk\/media\/for-organisations\/guide-to-data-protection\/guide-to-the-general-data-protection-regulation-gdpr-1-0.pdf."},{"issue":"4","key":"5240_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","volume":"63","author":"PJ Ruane","year":"2013","unstructured":"Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449\u201355.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"5240_CR24","doi-asserted-by":"publisher","first-page":"5917","DOI":"10.1128\/AAC.01151-15","volume":"59","author":"NA Margot","year":"2015","unstructured":"Margot NA, Johnson A, Miller MD, Callebaut C. Characterization of HIV-1 resistance to Tenofovir Alafenamide in vitro. Antimicrob Agents Chemother. 2015;59(10):5917\u201324.","journal-title":"Antimicrob Agents Chemother"},{"key":"5240_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antivir Res. 2016;125:63\u201370.","journal-title":"Antivir Res"},{"issue":"1","key":"5240_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jac\/dkh009","volume":"53","author":"D Turner","year":"2004","unstructured":"Turner D, Brenner B, Wainberg MA. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J Antimicrob Chemother. 2004;53(1):53\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"5240_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/381784","volume":"189","author":"MD Miller","year":"2004","unstructured":"Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837\u201346.","journal-title":"J Infect Dis"},{"key":"5240_CR28","volume-title":"MARVEL on RT mutations at position","author":"Stanford University HIV Drug Resistance Database","year":"2015","unstructured":"Stanford University HIV Drug Resistance Database. MARVEL on RT mutations at position; 2015. Available from: https:\/\/hivdb.stanford.edu\/cgi-bin\/Marvel.cgi?pos=215&drug=TDF&class=NRTI."},{"issue":"11","key":"5240_CR29","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.47.11.3478-3484.2003","volume":"47","author":"K Wolf","year":"2003","unstructured":"Wolf K, Walter H, Beerenwinkel N, Keulen W, Kaiser R, Hoffmann D, et al. Tenofovir resistance and resensitization. Antimicrob Agents Chemother. 2003;47(11):3478\u201384.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5240_CR30","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1128\/AAC.46.4.1067-1072.2002","volume":"46","author":"PR Harrigan","year":"2002","unstructured":"Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother. 2002;46(4):1067\u201372.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"5240_CR31","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","volume":"4","author":"L Ciaffi","year":"2017","unstructured":"Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, et al. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Lancet HIV. 2017;4(9):e384\u2013e92.","journal-title":"Lancet HIV"},{"issue":"12","key":"5240_CR32","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral activity of Bictegravir (GS-9883), a novel potent HIV-1 Integrase Strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60(12):7086\u201397.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5240_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1056\/NEJMoa1311274","volume":"371","author":"NI Paton","year":"2014","unstructured":"Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014;371(3):234\u201347.","journal-title":"N Engl J Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05240-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-020-05240-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05240-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T23:16:20Z","timestamp":1626736580000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05240-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5240"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05240-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial protocol has been approved by the Health Research Authority, UK (19\/LO\/0905). All patients in the trial will provide written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CI has received honoraria, support to attend conferences and research funding (paid to university of Sussex) from Gilead Sciences. DC has received honoraria and support to attend conferences from Gilead Sciences and ViiV. LW has received speaker\/advisory fees or conference support from Gilead, ViiV, Janssen, MSD, Cipla and Mylan. CO has been a recipient of grants, speaker\u2019s bureau and travel sponsorship from Gilead, MSD, ViiV, GSK and Janssen. NP has received honoraria for services rendered to Gilead Sciences. AMG receives personal consultancy fees from Roche Pharma, provides consulting services to Gilead Sciences, Janssen, and ViiV (paid to the University of Liverpool) and is the recipient of research funding from Gilead, Roche Pharma, and ViiV (paid to the University of Liverpool). All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"524"}}